Everything we've seen

1. ·Nov 15, 11:30 AMstreamnews

   Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

   Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

2. ·Nov 15, 11:30 AMstreamnews

   S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

   S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

3. ·Nov 15, 11:15 AMstreamnews

   Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

   Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

4. ·Nov 15, 11:15 AMstreamnews

   S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

   S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

5. ·Nov 15, 11:00 AMstreamnews

   Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

   Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

6. ·Nov 15, 11:00 AMstreamnews

   S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

   S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

7. ·Nov 15, 10:45 AMstreamnews

   Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

   Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

8. ·Nov 15, 10:45 AMstreamnews

   S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

   S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

9. ·Nov 15, 10:30 AMstreamnews

   Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

   Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

10. ·Nov 15, 10:30 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

11. ·Nov 15, 10:15 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

12. ·Nov 15, 10:15 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

13. ·Nov 15, 10:00 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

14. ·Nov 15, 10:00 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

15. ·Nov 15, 9:45 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

16. ·Nov 15, 9:45 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

17. ·Nov 15, 9:30 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

18. ·Nov 15, 9:30 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

19. ·Nov 15, 9:15 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

20. ·Nov 15, 9:15 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

21. ·Nov 15, 9:00 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

22. ·Nov 15, 9:00 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

23. ·Nov 15, 8:45 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

24. ·Nov 15, 8:45 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

25. ·Nov 15, 8:30 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

26. ·Nov 15, 8:30 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

27. ·Nov 15, 8:15 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

28. ·Nov 15, 8:15 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

29. ·Nov 15, 8:01 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

30. ·Nov 15, 8:01 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

31. ·Nov 15, 7:45 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

32. ·Nov 15, 7:45 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

33. ·Nov 15, 7:30 AMstreamnews

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

34. ·Nov 15, 7:30 AMstreamnews

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

35. ❖Nov 15, 1:07 AMnewsvia finnhub

    Humana (HUM) Launched A New Cancer Care Model

    Humana (NYSE:HUM) introduced a new cancer care model with Evolent Health and American Oncology Network, focused on quality and affordability. The collaboration uses advanced data analytics and real time insights to support oncologists and reduce prior authorization friction. The program targets cancer care management pain points for patients and clinicians, including treatment coordination and administrative workload. The new cancer care model with Evolent Health and American Oncology...

36. ?Nov 13, 10:21 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    HUM is down 1.66% today, a moderate but not outsized move. The most recent headline (09:50 ET) described HUM as 'nearing a breakout with perfect technical and setup scores,' which is bullish framing and suggests the downward move may be working against the prevailing technical sentiment rather than with it — this creates fade pressure on the downside continuation. The macro context shows a flattening yield curve (T10Y2Y at 2.0σ below trend), which is modestly supportive for defensive/managed care names like HUM, further tempering downside momentum. No major negative catalyst is identifiable. With 325 minutes remaining (roughly 5.4 hours — this appears to be an early-session read with most of the day ahead), there is ample time for the move to either continue or reverse, which is a neutral timing factor. The absence of a clear downside catalyst, the bullish technical framing in the morning headline, and the defensive sector tailwind from the macro environment collectively argue against high-conviction continuation. The move does not appear driven by strong negative flow with an obvious catalyst, making fade plausible. Setting probability at the floor threshold given the conflicting signals.

37. !Nov 13, 10:21 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    HUM is down 1.66% today, a moderate but not outsized move. The most recent headline (09:50 ET) described HUM as 'nearing a breakout with perfect technical and setup scores,' which is bullish framing and suggests the downward move may be working against the prevailing technical sentiment rather than with it — this creates fade pressure on the downside continuation. The macro context shows a flattening yield curve (T10Y2Y at 2.0σ below trend), which is modestly supportive for defensive/managed care names like HUM, further tempering downside momentum. No major negative catalyst is identifiable. With 325 minutes remaining (roughly 5.4 hours — this appears to be an early-session read with most of the day ahead), there is ample time for the move to either continue or reverse, which is a neutral timing factor. The absence of a clear downside catalyst, the bullish technical framing in the morning headline, and the defensive sector tailwind from the macro environment collectively argue against high-conviction continuation. The move does not appear driven by strong negative flow with an obvious catalyst, making fade plausible. Setting probability at the floor threshold given the conflicting signals.

38. ❖Nov 13, 8:36 AMnewsvia finnhub

    S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall

    S&P 500 premarket movers: Travelers, Palo Alto Networks and Domino's gain before the open, while Cisco and Advanced Micro Devices decline.

39. ❖Nov 13, 4:50 AMnewsvia finnhub

    Humana (NYSE:HUM) Nears Breakout With Perfect Technical and Setup Scores

    Humana (HUM) scores perfect 10 technical and setup ratings, trades near 52-week highs, and eyes a breakout above 451.01 with defined support risk.

40. ❖Nov 12, 2:07 PMnewsvia finnhub

    What Could Go Wrong At CVS Health From Here?

    For questions about this article or underlying research, email help@trefis.com.

41. ?Nov 12, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    HUM is down ~1.90% with ~365 minutes remaining (essentially a full trading day ahead still, suggesting this is an early-session read with ample time for continuation). The move is meaningful — nearly 2% — indicating real selling pressure with conviction. There is no news specific to HUM today, but absence of news is not a disqualifier; this could be sector rotation, managed care pressure, or technical selling through a key level. The macro context (T10YIE at 1.7σ below trend, i.e., lower real rates) is modestly supportive of defensive/insurance names like HUM, which creates a mild headwind against further downside continuation — this is a reason not to push probability higher. However, the magnitude of the move and time remaining support at least ordinary momentum continuation. No reversal signals are evident from the data provided. Net assessment: modest continuation probability — no strong tailwind but no clear fade catalyst either. Probability set at 0.54, triggering a short position with tight stops per system rules.

42. !Nov 12, 9:40 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    HUM is down ~1.90% with ~365 minutes remaining (essentially a full trading day ahead still, suggesting this is an early-session read with ample time for continuation). The move is meaningful — nearly 2% — indicating real selling pressure with conviction. There is no news specific to HUM today, but absence of news is not a disqualifier; this could be sector rotation, managed care pressure, or technical selling through a key level. The macro context (T10YIE at 1.7σ below trend, i.e., lower real rates) is modestly supportive of defensive/insurance names like HUM, which creates a mild headwind against further downside continuation — this is a reason not to push probability higher. However, the magnitude of the move and time remaining support at least ordinary momentum continuation. No reversal signals are evident from the data provided. Net assessment: modest continuation probability — no strong tailwind but no clear fade catalyst either. Probability set at 0.54, triggering a short position with tight stops per system rules.

43. ❖Nov 12, 7:00 AMnewsvia finnhub

    As AI Outpaces Companies’ Ability to Manage It, Axway Gives Enterprises Control of What Their AI Does and What It Costs

    SCOTTSDALE, Ariz., November 12, 2026--Enterprises are racing to put AI to work, but many still can't account for what it costs or how it uses company data to make decisions across disparate systems. Today Axway, a 74Software company (Euronext: 74SW) trusted by more than 4,000 organizations, introduced Amplify Platform to close that gap. The platform gives enterprises, including those in highly regulated industries, a foundation to securely connect, govern and orchestrate the APIs, integrations,

44. ❖Nov 12, 5:16 AMnewsvia finnhub

    Wells Fargo Maintains Overweight on Humana, Raises Price Target to $602

    Wells Fargo analyst Stephen Baxter maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $502 to $602.

45. ❖Nov 11, 1:08 PMnewsvia finnhub

    Humana (HUM) Stock Gets Fair Value Bump After Star Ratings And Q3 Beat

    The latest valuation work on Humana lifts the assessed fair value from US$465.13 to US$475.54, signaling a modest reset in price targets. Analysts linking this move to recent Q3 results and improved Medicare Advantage Star Ratings describe a generally constructive mood, even as some still flag policy and execution risks. Read on to see what is driving the shifting Humana story and how you can track the next turns in this narrative. Analyst Price Targets don't always capture the full story...

46. ❖Nov 11, 12:13 PMnewsvia finnhub

    Can HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?

    Humana's new oncology model aims to speed cancer treatment, reduce administrative hurdles and advance its value-based care strategy through data analytics.

47. ❖Nov 11, 11:00 AMnewsvia finnhub

    Humana (HUM) Upgraded to Strong Buy: Here's Why

    Humana (HUM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

48. ❖Nov 11, 7:50 AMnewsvia finnhub

    TD Cowen Maintains Hold on Humana, Raises Price Target to $430

    TD Cowen analyst Ryan Langston maintains Humana (NYSE:HUM) with a Hold and raises the price target from $370 to $430.

49. ❖Nov 10, 3:06 PMnewsvia finnhub

    S&P 500 Top Gainers and Losers for Today's Session

    S&P 500 market movers for today's session: Charter Communications led gainers at 9.68%, while Carvana led losers at 6.32%.

50. ❖Nov 10, 12:36 PMnewsvia finnhub

    S&P 500 Top Movers: Today's US Session Gainers and Losers

    S&P 500 top movers for today's US session: Take-Two Interactive led gainers at 7.57%, while GE Vernova led decliners at 7.19%.

51. ✓Nov 10, 12:05 PMdecisionacted

    Agent 7 — Day Trader — decide: buy

    HUM is up 3.18% intraday, a meaningful move showing real conviction and institutional flow. The catalyst is a positive partnership announcement (Humana/Evolent/AON oncology model eliminating prior auth burden), which is a favorable managed care headline reducing administrative cost overhang — a credible driver for the move. With 220 minutes remaining there is ample time for continuation. However, the macro context (DFF at 2.0σ above 24-month trend) reflects elevated rates, which is a mild headwind for managed care valuations but not acutely sector-disruptive today. No reversal pattern is evident from the data provided. The move is at the lower end of the 2-5% range and the news is incremental rather than a major earnings beat or guidance raise, suggesting moderate rather than strong continuation pressure. Overall, the balance of evidence supports modest continuation — the trade is worth taking given the bounded risk structure, but this is not a high-conviction 0.7+ setup.

52. ❖Nov 10, 10:00 AMnewsvia finnhub

    New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden

    LOUISVILLE, Ky., November 10, 2026--New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden

53. ❖Nov 10, 9:04 AMnewsvia finnhub

    Why Is Humana Stock Trading Higher Tuesday?

    Humana (HUM) stock jumped over 3% following a new cancer care initiative and a raised 2026 earnings outlook. Read the latest updates.

54. ❖Nov 10, 7:43 AMnewsvia finnhub

    JP Morgan Maintains Neutral on Humana, Raises Price Target to $484

    JP Morgan analyst Lisa Gill maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $393 to $484.

55. ❖Nov 10, 6:03 AMnewsvia finnhub

    Humana Partners With Evolent Health, American Oncology Network To Introduce New Cancel Care Model In 8 U.S. States

    Humana Inc., in collaboration with Evolent Health, Inc. and American Oncology Network (AON), today announced the launch of a new cancer care model designed to improve the quality, timeliness and affordability of cancer

56. ❖Nov 9, 11:18 PMnewsvia finnhub

    Humana Inc. Launches Cash Tender Offers for Up to $1,500,000,000 of Outstanding Debt Securities

57. ▢Nov 9, 7:00 PMjournal

    Agent 7 — Day Trader opened long 6 @ $436.66

58. ▣Nov 9, 7:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 6 @ $437.99 (+$7.98)

    EOD forced close — day trader never carries overnight

59. ❖Nov 9, 11:36 AMnewsvia finnhub

    Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

    Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the mark

60. ❖Nov 9, 8:23 AMnewsvia finnhub

    Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities

    LOUISVILLE, Ky., November 09, 2026--Humana Inc. (NYSE: HUM) ("Humana", "we", or "our") today announced that it has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the "Offer to Purchase").

61. ❖Nov 9, 8:17 AMnewsvia finnhub

    Humana Analysts Raise Their Forecasts After Q3 Results

    Humana beat Q3 loss and revenue estimates, raised 2026 EPS guidance, and saw analysts lift price targets to $495-$587.

62. ❖Nov 9, 8:12 AMnewsvia finnhub

    Piper Sandler Maintains Overweight on Humana, Raises Price Target to $526

    Piper Sandler analyst Jessica Tassan maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $463 to $526.

63. ❖Nov 9, 6:39 AMnewsvia finnhub

    Guggenheim Maintains Buy on Humana, Raises Price Target to $521

    Guggenheim analyst Jason Cassorla maintains Humana (NYSE:HUM) with a Buy and raises the price target from $471 to $521.

64. ❖Nov 9, 6:38 AMnewsvia finnhub

    Barclays Maintains Overweight on Humana, Raises Price Target to $587

    Barclays analyst Andrew Mok maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $582 to $587.

65. ❖Nov 9, 5:21 AMnewsvia finnhub

    Company News for Nov 9, 2026

    Companies In The News Are:FLY,ASTS,LRCX,HUM and BEN

66. ❖Nov 9, 4:26 AMnewsvia finnhub

    Humana Commences Cash Tender Offers For Outstanding Senior Notes With $1.5B Tender Cap

    Humana Inc. (NYSE:HUM) ("Humana", "we", or "our") today announced that it has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below,

67. ❖Nov 9, 3:08 AMnewsvia finnhub

    Cantor Fitzgerald Maintains Overweight on Humana, Raises Price Target to $495

    Cantor Fitzgerald analyst Sarah James maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $460 to $495.

68. ❖Nov 7, 9:34 PMnewsvia finnhub

    Medicare Just Locked In Most of Your 2027 Costs. One Big Number Is Still Missing

    Medicare open enrollment ends Dec. 7, and most 2027 costs are set: a $2,400 Part D cap, a $700 deductible and a 3.6% COLA. For a 72-year-old with one costly drug, the bill rises $300, her check nets about $76 more a month, and a plan comparison is worth $408.

69. ❖Nov 7, 8:14 PMnewsvia finnhub

    What Humana (HUM) Said on Its Q3 Earnings Call

    Humana (NYSE:HUM) raised its full-year 2026 adjusted earnings outlook and said early Medicare Advantage enrollment trends point to membership growth in 2027, as executives described progress toward a longer-term margin recovery. The health insurer now expects adjusted earnings of at least $9.50 per

70. ❖Nov 7, 5:09 AMnewsvia finnhub

    What Did CVS Health's Quarter Change For Its Stock?

    For questions about this article or underlying research, email help@trefis.com.

71. ❖Nov 6, 10:30 PMnewsvia finnhub

    How To Earn $500 A Month From Humana Stock Ahead Of Q3 Earnings

    Humana Inc. investors may be eyeing potential dividend gains ahead of the company’s third-quarter earnings report on Friday, Nov. 6. Currently, Humana has an annual dividend yield of 0.85%, with a quarterly dividend of 88.5 cents per share ($3.54 a...

72. ❖Nov 6, 7:11 PMnewsvia finnhub

    How Earnings Upgrades At Intuitive Surgical Stock Have Changed Its Investment Story

    Intuitive Surgical recently added Aaron Martin, currently President of Insurance at Humana and former Amazon healthcare executive, to its board, expanding the board from 10 to 11 directors effective January 1, 2027. Martin’s mix of telehealth, payer, and health system experience directly connects Intuitive Surgical’s robotics platform to real world reimbursement, digital care delivery, and hospital budget constraints. We will look at how Intuitive Surgical’s investment narrative is shaped by...

73. ❖Nov 6, 5:14 PMnewsvia finnhub

    What Should Investors Watch After Intuitive Surgical (ISRG) Added Aaron Martin To Its Board?

    Intuitive Surgical (NasdaqGS: ISRG) has appointed healthcare executive Aaron Martin to its board of directors, effective January 2027. Martin previously led Amazon Health Services and has held senior roles at Humana and Providence St. Joseph Health. His background spans digital health, telemedicine initiatives, and insurance operations across large US healthcare systems. There is more to assess at Intuitive Surgical than the upcoming 2027 board appointment of Aaron Martin. Our analysis turns...

74. ❖Nov 6, 4:15 PMnewsvia finnhub

    Humana Inc (HUM) (Q3 2026) Earnings Call Highlights: Raised EPS Outlook, Star Ratings Momentum ...

    Humana Inc (HUM) lifted its 2026 adjusted EPS guidance to at least $9.50, posted a 4.17 member-weighted Star rating for bonus year 2028, and now expects Medicare Advantage membership growth in 2027.

75. ❖Nov 6, 1:48 PMnewsvia finnhub

    Humana Inc. Q3 2026 Earnings Call Summary

    Moby summary of Humana Inc.'s Q3 2026 earnings call

76. ❖Nov 6, 1:22 PMnewsvia finnhub

    Humana (HUM) Q3 2026 Earnings Call Transcript

    Humana's Star rating gains and new BlackRock partnership shape its 2027 margin outlook.

77. ❖Nov 6, 12:27 PMnewsvia finnhub

    HUM Q3 Earnings Beat Estimates on Strong Insurance Performance

    Humana's Q3 2026 loss is narrower than expected as Medicare membership and premiums grow, prompting a guidance hike despite rising benefit costs and expenses.

78. ❖Nov 6, 11:02 AMnewsvia finnhub

    Humana Stock Gets a Boost From Unexpected Decline in Medical Costs

    Humana had a narrower-than-expected quarterly loss, with its Medicare business under pressure.

79. ❖Nov 6, 10:53 AMnewsvia finnhub

    HUM vs UNH: valuation and profitability compared

    Investing.com -- Unitedhealth Group (UNH) offers the stronger valuation and income profile, while Humana Inc (HUM) offers faster recent growth but much thinner profitability.

80. ✓Nov 6, 10:36 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    HUM is up 2.55% on earnings catalyst: beat on EPS and revenue, raised FY2026 adjusted EPS guidance. The headlines are broadly positive — beats on earnings and revenue, raised outlook — with some mixed signals noted (insurance business remains pressured, full-year sales guidance light vs estimates). This mixed-but-net-positive earnings picture is consistent with an initial pop that may continue to digest favorably into the close as investors focus on the guidance raise and medical cost surprise. With 310 minutes remaining (essentially a full trading session still ahead), there is ample time for continuation. The macro context (elevated mortgage rates) is not relevant to HUM. The stock hasn't gapped to an extreme level (2.55% is a solid but not exhausted move), and the raised EPS guidance gives fundamental buyers a reason to hold or add. The 'mixed' characterization in some headlines introduces some uncertainty and could limit upside, but the balance of evidence favors continuation over fade. No reversal signal is apparent from the data provided.

81. ❖Nov 6, 9:52 AMnewsvia finnhub

    Humana Inc. Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Adjusted EPS Guidance

82. ❖Nov 6, 9:39 AMnewsvia finnhub

    CVS and UnitedHealth lost ground on Medicare ratings. Who gained?

    Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

83. ❖Nov 6, 9:29 AMnewsvia finnhub

    Great Jobs Report. Will It Matter to Market Participants?

    BLS results were far better than expected: +165K, close to triple the +59K analysts were looking for.

84. ❖Nov 6, 8:30 AMnewsvia finnhub

    Humana (HUM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

    While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

85. ❖Nov 6, 7:54 AMnewsvia finnhub

    Humana Raises 2026 Earnings Outlook After Third-Quarter Revenue Jumps 26%

    Humana Inc. (NYSE:HUM) reported better-than-expected third-quarter 2026 earnings and revenue, prompting the health insurer to raise its full-year profit guidance.

86. ❖Nov 6, 7:26 AMnewsvia finnhub

    Humana (NYSE:HUM) Posts Mixed Q3 Results and Raises FY2026 Adjusted EPS Guidance

    Humana's mixed Q3 2026 results met revenue views, adjusted loss was narrower, and FY adjusted EPS guidance rose, though shares dipped premarket.

87. ❖Nov 6, 7:23 AMnewsvia finnhub

    Humana expects another year of Medicare Advantage membership growth in 2027

    More seniors than expected signing up for Humana’s plans in 2026 was a major concern for investors. But Humana is in a much better position to absorb future growing pains, executives said.

88. ❖Nov 6, 7:19 AMnewsvia finnhub

    Humana beats estimates on earnings and revenue, raises guidance

    Investing.com -- Humana Inc. (NYSE: HUM) reported third-quarter results that exceeded analyst expectations and raised its full-year earnings guidance, though shares slipped 0.8% following the announcement.

89. ❖Nov 6, 7:08 AMnewsvia finnhub

    Humana’s Medical Costs Offer a Surprise, While Its Insurance Business Remains Pressured

    Humana’s medical costs are lower than expected, but its Medicare business remains under pressure.

90. ❖Nov 6, 6:46 AMnewsvia finnhub

    Humana’s (NYSE:HUM) Q3 2026 sales top estimates but full-year sales guidance misses expectations

    Health insurance company Humana (NYSE:HUM) announced better-than-expected revenue in Q3 2026, with revenue up 26.1% year on year to $41.16 billion. On the other hand, the company’s full-year revenue guidance of $160 billion at the midpoint came in 1.7% below analysts’ consensus estimates. Its non-GAAP loss of $0.70 per share was 30.3% above analysts’ consensus estimates.

91. ❖Nov 6, 6:37 AMnewsvia finnhub

    Humana Stock Rises After Narrower-Than-Expected Loss, Raised 2026 Profit Outlook

    Humana posted a narrower-than-expected third-quarter adjusted loss of 70 cents per share on revenue of $41.16 billion, above estimates, and raised its 2026 adjusted EPS guidance to at least $9.50. The insurer said its 2027 Medicare Advantage bids should drive progress toward a pre-tax margin of at least 3% in 2028.

92. ❖Nov 6, 6:30 AMnewsvia finnhub

    Humana (HUM) Reports Q3 Loss, Beats Revenue Estimates

    Humana (HUM) delivered earnings and revenue surprises of +32.04% and +0.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

93. ▢Nov 5, 7:00 PMjournal

    Agent 7 — Day Trader opened long 7 @ $422.30

94. ▣Nov 5, 7:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 7 @ $434.20 (+$83.30)

    EOD forced close — day trader never carries overnight

95. ?Nov 5, 3:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 5 minutes remaining until the forced close, there is virtually no time for the move to continue meaningfully even if momentum were intact. The -1.88% move is below the 2-5% threshold that signals strong conviction flow. The Baron Health Care headline noting 'trough 2026 earnings' suggests a value buyer is stepping in at these levels, implying potential support/reversal sentiment from institutional players. Macro context (elevated DFF) is sector-neutral for managed care. The combination of minimal time remaining and a possible contrarian institutional bid makes continuation unlikely — the dominant factor here is simply the 5-minute window, which makes any directional trade impractical and the probability of meaningful further downside into close very low.

96. !Nov 5, 3:40 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    With only 5 minutes remaining until the forced close, there is virtually no time for the move to continue meaningfully even if momentum were intact. The -1.88% move is below the 2-5% threshold that signals strong conviction flow. The Baron Health Care headline noting 'trough 2026 earnings' suggests a value buyer is stepping in at these levels, implying potential support/reversal sentiment from institutional players. Macro context (elevated DFF) is sector-neutral for managed care. The combination of minimal time remaining and a possible contrarian institutional bid makes continuation unlikely — the dominant factor here is simply the 5-minute window, which makes any directional trade impractical and the probability of meaningful further downside into close very low.

97. ?Nov 5, 3:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

98. !Nov 5, 3:21 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

99. ?Nov 5, 3:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

100. !Nov 5, 3:21 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

101. ?Nov 5, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

102. ?Nov 5, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

103. !Nov 5, 2:20 PMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

104. !Nov 5, 2:20 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

105. ?Nov 5, 1:22 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

106. !Nov 5, 1:22 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

107. ?Nov 5, 1:22 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

108. !Nov 5, 1:22 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     The single most dominant risk factor here is that earnings are IMMINENT — reporting tomorrow (2026-11-06, BMO) with consensus EPS of -$1.01, signaling a trough earnings environment. The Baron Health Care Fund headline explicitly frames this as "trough 2026 earnings," confirming the market is aware of near-term fundamental weakness. The broader macro environment is severely risk-off today (SPY -3.99%, QQQ -5.88%, VXX +27.02%), which adds further near-term headwind. While the healthcare sector is showing strong 30-day relative strength (+12.53pts vs SPY), HUM's idiosyncratic drop in a strong sector suggests company-specific concerns. Options flow is below average on both calls and puts (both z-scores negative), offering no unusual bullish confirmation, and there are no insider purchases in the last 30 days.

109. ?Nov 5, 12:50 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is down ~2% intraday, a meaningful move suggesting real selling pressure. Headlines are centered on earnings preview context (Q3 estimates, premium dynamics), which creates uncertainty rather than a clear bullish catalyst to reverse the selloff. The broader managed care sector (CNC hitting fresh highs, ELV analysis) shows mixed signals with peers not uniformly weak, which limits sector-wide panic as a driver. Macro context (elevated fed funds rate ~2.1σ above trend) is modestly negative for capital-intensive healthcare names but not a primary driver here. With 175 minutes remaining there is meaningful time for continuation, but no strong headline catalyst is driving the move, and earnings-preview nervousness tends to produce slow bleeds rather than sharp accelerations. No clear reversal pattern is evident from the data provided. Overall, modest continuation bias — the selling pressure appears real but lacks a strong accelerant, so probability sits just above 0.5.

110. !Nov 5, 12:50 PMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     HUM is down ~2% intraday, a meaningful move suggesting real selling pressure. Headlines are centered on earnings preview context (Q3 estimates, premium dynamics), which creates uncertainty rather than a clear bullish catalyst to reverse the selloff. The broader managed care sector (CNC hitting fresh highs, ELV analysis) shows mixed signals with peers not uniformly weak, which limits sector-wide panic as a driver. Macro context (elevated fed funds rate ~2.1σ above trend) is modestly negative for capital-intensive healthcare names but not a primary driver here. With 175 minutes remaining there is meaningful time for continuation, but no strong headline catalyst is driving the move, and earnings-preview nervousness tends to produce slow bleeds rather than sharp accelerations. No clear reversal pattern is evident from the data provided. Overall, modest continuation bias — the selling pressure appears real but lacks a strong accelerant, so probability sits just above 0.5.

111. ?Nov 3, 2:00 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is up ~2% today with a modestly positive catalyst — the athenahealth prior authorization expansion is an operational/administrative positive that reduces friction for physicians and could support sentiment around Humana's managed care efficiency narrative. However, this is a soft, non-financial headline unlikely to drive sustained institutional buying pressure. The macro backdrop (DFF elevated ~2.2σ above trend) is mildly negative for equities broadly but most reactive to banks/money-markets, not managed care. With 105 minutes remaining there is reasonable time for continuation if momentum persists, but the move is already at the upper end of 'modest' (2%) and may have captured most of the day's upside. No reversal signals are explicitly present, no fade pattern described, so default leans slightly toward continuation. Probability is kept modest given the soft news driver and no evidence of unusually strong volume or sector tailwind.

112. !Nov 3, 2:00 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     HUM is up ~2% today with a modestly positive catalyst — the athenahealth prior authorization expansion is an operational/administrative positive that reduces friction for physicians and could support sentiment around Humana's managed care efficiency narrative. However, this is a soft, non-financial headline unlikely to drive sustained institutional buying pressure. The macro backdrop (DFF elevated ~2.2σ above trend) is mildly negative for equities broadly but most reactive to banks/money-markets, not managed care. With 105 minutes remaining there is reasonable time for continuation if momentum persists, but the move is already at the upper end of 'modest' (2%) and may have captured most of the day's upside. No reversal signals are explicitly present, no fade pattern described, so default leans slightly toward continuation. Probability is kept modest given the soft news driver and no evidence of unusually strong volume or sector tailwind.

113. ✓Nov 2, 5:01 PMdecisionacted

     Agent 4 — Dip Buyer (Frozen) — decide: buy

     Humana is a large, established managed care insurer with no company-specific negative catalysts visible in the available evidence — no guidance cuts, accounting issues, or sector collapse are flagged. The recent news headline is mildly positive, suggesting HUM may beat earnings estimates again, which supports the view that the ~10% pullback from the 30-day high is more likely technical/sentiment-driven than fundamentally justified. The macro context (elevated mortgage rates) is largely irrelevant to Humana's core Medicare Advantage and health insurance business, further supporting the view that the dip is not fundamentally driven.

114. ?Nov 2, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

115. !Nov 2, 1:20 PMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

116. ?Nov 2, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

117. !Nov 2, 1:20 PMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

118. ?Nov 2, 11:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

119. !Nov 2, 11:21 AMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

120. ?Nov 2, 10:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

121. !Nov 2, 10:21 AMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

122. ?Nov 2, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

123. !Nov 2, 10:21 AMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

124. ?Oct 30, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

125. !Oct 30, 1:20 PMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

126. ?Oct 30, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

127. !Oct 30, 1:20 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

128. ?Oct 29, 3:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

129. !Oct 29, 3:21 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

130. ?Oct 29, 3:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

131. !Oct 29, 3:21 PMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

132. ?Oct 29, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

133. !Oct 29, 2:20 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto applies: earnings are imminent in 8 days (2026-11-06) with a deeply negative consensus EPS of -$0.93, creating a high-risk binary event that structurally undermines a 90-day swing trade thesis. The override conditions are not met — there is no insider cluster buying (zero Form 4 activity in 30 days), options flow is slightly put-skewed (P/C ratio 1.28, both volumes below z-score thresholds for "unusual"), and recent news about 1 million Medicare Advantage plan cancellations signals idiosyncratic fundamental headwinds for HUM specifically. Additionally, the stock is declining while its sector (Health Care/XLV) is actually outperforming SPY by +4.70pts over 30 days, flagging this as a single-stock idiosyncratic problem rather than sector-wide noise.

134. ?Oct 29, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

135. !Oct 29, 2:20 PMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.2% from its 30-day high, a meaningful but not extreme decline. However, the dominant risk factor here is imminent earnings in 8 days (2026-11-06) with a consensus EPS of -$0.93, signaling expectations of a net loss — a significant negative signal for a managed care company. The negative news headline about Medicare Advantage plan cancellations affecting ~1M Americans directly targets HUM's core business, suggesting ongoing structural headwinds in MA rather than a temporary dip. Sector strength (XLV ranked #1, +4.70pts vs SPY) indicates HUM is underperforming its sector on an idiosyncratic basis, not caught in broad selling. Options flow shows a slightly elevated P/C ratio (1.28) with sub-normal volumes on both sides — no bullish confirmation signal. No insider buying to indicate internal conviction at these levels.

136. ?Oct 20, 2:25 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is up 3.50% intraday, a meaningful move suggesting real institutional flow. No headlines are available to explain the catalyst, but absence of news doesn't negate the momentum signal — managed care names can move on sector rotation, CMS news, or positioning. The macro backdrop (elevated 2Y rates at 2.0σ above trend) is modestly negative for rate-sensitive equities broadly, but HUM as a managed care/insurance name is not highly duration-sensitive and may even benefit from a higher-rate environment through investment income. With 80 minutes remaining there is reasonable time for continuation, though not enough to expect a full second leg. The 3.50% move is at the lower end of 'strong' territory and without a clear catalyst or volume confirmation data, I cannot assign high conviction for continuation. No reversal pattern is evident from available data. Overall, the setup is a mild momentum continuation — above 0.5 but without strong tailwinds to push into the high-conviction tier.

137. !Oct 20, 2:25 PMsignalseverity 0.04

     Agent 7 — Day Trader — day_trade_skipped

     HUM is up 3.50% intraday, a meaningful move suggesting real institutional flow. No headlines are available to explain the catalyst, but absence of news doesn't negate the momentum signal — managed care names can move on sector rotation, CMS news, or positioning. The macro backdrop (elevated 2Y rates at 2.0σ above trend) is modestly negative for rate-sensitive equities broadly, but HUM as a managed care/insurance name is not highly duration-sensitive and may even benefit from a higher-rate environment through investment income. With 80 minutes remaining there is reasonable time for continuation, though not enough to expect a full second leg. The 3.50% move is at the lower end of 'strong' territory and without a clear catalyst or volume confirmation data, I cannot assign high conviction for continuation. No reversal pattern is evident from available data. Overall, the setup is a mild momentum continuation — above 0.5 but without strong tailwinds to push into the high-conviction tier.

138. ?Oct 20, 10:55 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is up 2.81% intraday, a meaningful move reflecting real institutional flow. There is no directly attributable news headline for HUM today — the TempraMed headline is unrelated — which is common and not a disqualifier. The macro context shows elevated 2-year yields (~4.74, 2σ above trend), which is a mild headwind for managed care/insurance names like HUM due to discount rate sensitivity and potential pressure on investment income assumptions, but this is not a dominant intraday driver. With 290 minutes remaining (roughly a full session still ahead), there is ample time for continuation. The move is in the lower range of the 2-5% significance band, suggesting early-to-mid session conviction but not an extreme gap. No reversal pattern or fade signal is evident from the data provided. On balance, momentum slightly favors continuation into the close with no strong reason to expect a fade, but the elevated rate environment and absence of a positive catalyst cap confidence at a modest continuation probability.

139. !Oct 20, 10:55 AMsignalseverity 0.03

     Agent 7 — Day Trader — day_trade_skipped

     HUM is up 2.81% intraday, a meaningful move reflecting real institutional flow. There is no directly attributable news headline for HUM today — the TempraMed headline is unrelated — which is common and not a disqualifier. The macro context shows elevated 2-year yields (~4.74, 2σ above trend), which is a mild headwind for managed care/insurance names like HUM due to discount rate sensitivity and potential pressure on investment income assumptions, but this is not a dominant intraday driver. With 290 minutes remaining (roughly a full session still ahead), there is ample time for continuation. The move is in the lower range of the 2-5% significance band, suggesting early-to-mid session conviction but not an extreme gap. No reversal pattern or fade signal is evident from the data provided. On balance, momentum slightly favors continuation into the close with no strong reason to expect a fade, but the elevated rate environment and absence of a positive catalyst cap confidence at a modest continuation probability.

140. ?Oct 19, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     A hard veto is triggered by the imminent earnings event on 2026-11-06 (18 days away — within the 15-30 day headwind window, but critically featuring a consensus EPS of -$0.93, signaling expected losses and meaningful uncertainty). None of the three veto-override conditions are met: there is no insider cluster buy (zero Form 4 activity in 30 days), options flow is below average on both calls and puts (call z=-0.62, put z=-0.53), and the fundamental picture is clouded by the negative consensus EPS. The sector (Health Care / XLV) is actually outperforming SPY on both 5d and 30d bases, meaning the HUM-specific drop is idiosyncratic rather than sector-wide noise, which is a negative signal. Signal scoring: no cluster buy, no unusual call volume, sector outperforming (idiosyncratic drop, -1), drop <15% so no mean-reversion bonus, earnings within 15-30 days (-1), VIX at 82nd percentile (-1), 10Y at 5.10% is a headwind for a managed-care value name (-1), and no offsetting positive signals beyond a mildly positive news sentiment on a value article. Net score is approximately -4, well below the buy threshold.

141. ?Oct 19, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.3% from its 30-day high, a moderate dip for a large managed-care insurer. The Health Care sector is outperforming SPY meaningfully (+5.42pts over 5 days, +3.27pts over 30 days), suggesting the drop is idiosyncratic rather than sector-driven — a flag for company-specific risk. The most critical concern is the upcoming earnings on 2026-11-06, just 18 days away, with a consensus EPS of -$0.93, indicating analysts expect a loss. This is a significant near-term binary risk that substantially limits the attractiveness of a swing entry. There are no insider cluster buys, options flow is below average in both calls and puts (both z-scores negative), and the 8-K filings contain no disclosed metrics to assess. A mildly positive news article asks if HUM is a value buy, but this is thin confirmation.

142. !Oct 19, 1:20 PMsignalseverity 0.10

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     A hard veto is triggered by the imminent earnings event on 2026-11-06 (18 days away — within the 15-30 day headwind window, but critically featuring a consensus EPS of -$0.93, signaling expected losses and meaningful uncertainty). None of the three veto-override conditions are met: there is no insider cluster buy (zero Form 4 activity in 30 days), options flow is below average on both calls and puts (call z=-0.62, put z=-0.53), and the fundamental picture is clouded by the negative consensus EPS. The sector (Health Care / XLV) is actually outperforming SPY on both 5d and 30d bases, meaning the HUM-specific drop is idiosyncratic rather than sector-wide noise, which is a negative signal. Signal scoring: no cluster buy, no unusual call volume, sector outperforming (idiosyncratic drop, -1), drop <15% so no mean-reversion bonus, earnings within 15-30 days (-1), VIX at 82nd percentile (-1), 10Y at 5.10% is a headwind for a managed-care value name (-1), and no offsetting positive signals beyond a mildly positive news sentiment on a value article. Net score is approximately -4, well below the buy threshold.

143. !Oct 19, 1:20 PMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     HUM is down 10.3% from its 30-day high, a moderate dip for a large managed-care insurer. The Health Care sector is outperforming SPY meaningfully (+5.42pts over 5 days, +3.27pts over 30 days), suggesting the drop is idiosyncratic rather than sector-driven — a flag for company-specific risk. The most critical concern is the upcoming earnings on 2026-11-06, just 18 days away, with a consensus EPS of -$0.93, indicating analysts expect a loss. This is a significant near-term binary risk that substantially limits the attractiveness of a swing entry. There are no insider cluster buys, options flow is below average in both calls and puts (both z-scores negative), and the 8-K filings contain no disclosed metrics to assess. A mildly positive news article asks if HUM is a value buy, but this is thin confirmation.

144. ?Oct 16, 3:10 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is down 3.18% today, which is a meaningful move, but several factors argue against continuation into the close. First, with only 35 minutes remaining until the forced close cutoff, there is very limited time for the move to extend a full +3% further — the time window materially reduces the expected payoff of a continuation trade. Second, the only visible headline references UnitedHealth's growth prospects, which is sector-adjacent but not a direct HUM catalyst, and notably the absence of a clear HUM-specific negative driver makes it harder to assess whether this is a sustained flow story or a sympathy/sector rotation move that may be nearing exhaustion. Third, a ~3% move in a managed care name like HUM without an obvious fundamental trigger (no earnings, no guidance cut visible in headlines) raises the possibility this is being faded into the close by intraday traders locking in gains on the short side. Fourth, macro context (elevated mortgage rates) is not meaningfully bearish for HUM's managed care business model. The combination of very limited time remaining and ambiguous catalyst backdrop tips this just below the 0.5 threshold — not a strong fade call, but not enough conviction to expect continuation.

145. !Oct 16, 3:10 PMsignalseverity -0.03

     Agent 7 — Day Trader — day_trade_skipped

     HUM is down 3.18% today, which is a meaningful move, but several factors argue against continuation into the close. First, with only 35 minutes remaining until the forced close cutoff, there is very limited time for the move to extend a full +3% further — the time window materially reduces the expected payoff of a continuation trade. Second, the only visible headline references UnitedHealth's growth prospects, which is sector-adjacent but not a direct HUM catalyst, and notably the absence of a clear HUM-specific negative driver makes it harder to assess whether this is a sustained flow story or a sympathy/sector rotation move that may be nearing exhaustion. Third, a ~3% move in a managed care name like HUM without an obvious fundamental trigger (no earnings, no guidance cut visible in headlines) raises the possibility this is being faded into the close by intraday traders locking in gains on the short side. Fourth, macro context (elevated mortgage rates) is not meaningfully bearish for HUM's managed care business model. The combination of very limited time remaining and ambiguous catalyst backdrop tips this just below the 0.5 threshold — not a strong fade call, but not enough conviction to expect continuation.

146. ?Oct 16, 1:20 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is down 3.57% intraday — a meaningful move representing real institutional flow. No direct HUM catalyst is visible in the headlines; the UnitedHealth growth story is competitor-focused and could indirectly weigh on managed care peers like HUM by highlighting competitive pressure, but this is a weak signal. The macro context (elevated mortgage rates) is not directly relevant to health insurers. With 145 minutes remaining there is ample time for the move to continue into the close. The absence of a bounce/reversal pattern and the magnitude of the drop (suggesting genuine selling pressure rather than a gap-and-fade) support mild continuation. However, without a confirmed HUM-specific catalyst, and given that a 3.5%+ drop can attract dip buyers in the afternoon session, conviction is moderate rather than high. No reversal signals are evident from the data provided. Overall: lean toward continuation of the downside move, but only modestly.

147. !Oct 16, 1:20 PMsignalseverity -0.04

     Agent 7 — Day Trader — day_trade_skipped

     HUM is down 3.57% intraday — a meaningful move representing real institutional flow. No direct HUM catalyst is visible in the headlines; the UnitedHealth growth story is competitor-focused and could indirectly weigh on managed care peers like HUM by highlighting competitive pressure, but this is a weak signal. The macro context (elevated mortgage rates) is not directly relevant to health insurers. With 145 minutes remaining there is ample time for the move to continue into the close. The absence of a bounce/reversal pattern and the magnitude of the drop (suggesting genuine selling pressure rather than a gap-and-fade) support mild continuation. However, without a confirmed HUM-specific catalyst, and given that a 3.5%+ drop can attract dip buyers in the afternoon session, conviction is moderate rather than high. No reversal signals are evident from the data provided. Overall: lean toward continuation of the downside move, but only modestly.

148. ✓Oct 14, 9:40 AMdecisionacted

     Agent 7 — Day Trader — decide: buy

     HUM is up 2.49% intraday, a meaningful move with real institutional conviction behind it. The catalyst is clear and positive: news that 95% of Humana's Medicare Advantage members will be in four-Star plans (up from 20%) is a significant quality/revenue improvement story that takes time to be fully digested and priced in by the market. Star ratings directly impact CMS bonus payments and plan attractiveness, so this is a material fundamental positive. The AngioDynamics NanoKnife coverage policy headline adds minor incremental positivity around MA utilization. The macro context (5Y forward inflation 1.5σ above trend) is a mild headwind for rate-sensitive sectors broadly, but managed care/health insurers are not highly rate-sensitive in their core business model, so this is a limited drag. With 365 minutes remaining (essentially a full remaining session), there is ample time for continued accumulation by investors who may still be processing the Star ratings upgrade. No reversal pattern is evident from the data provided — the move appears directionally sustained rather than fading. The only modest uncertainty is whether the move has already front-run the news sufficiently given the headline was from last evening, meaning some digestion may already be complete. On balance, momentum, positive fundamental catalyst, and ample remaining time support continuation.

149. ▢Oct 13, 8:00 PMjournal

     Agent 7 — Day Trader opened long 6 @ $430.84

150. ▣Oct 13, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 6 @ $423.56 (-$43.68)

     Long stop: close $423.56 ≤ stop $424.38

151. ?Oct 13, 1:05 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is currently down -1.80% on the day, but the most relevant news is actually bullish: UnitedHealth beat Q3 expectations and raised guidance, with headlines explicitly noting Humana advancing 2% on the UNH coat-tails (sector read-through on medical cost trends). The current -1.80% move in HUM appears inconsistent with the positive sector catalyst — UNH is up ~4% and HUM should benefit from the same cost-trend narrative. This suggests the early HUM weakness may be fading or that the headline capturing HUM +2% reflects a mid-session reversal already underway from a deeper intraday low. The setup here is a likely REVERSAL (up) rather than continuation of the down move. With 160 minutes remaining, there is ample time for HUM to recover toward the UNH-driven sector bid. The macro backdrop (yield curve steepening, T10Y3M elevated) is modestly negative for recession-sensitive managed care but is not the dominant force today versus the direct earnings catalyst. Probability reflects moderate confidence in upside continuation given the strong sector tailwind, time remaining, and apparent disconnect between HUM's current print and the positive UNH read-through.

152. !Oct 13, 1:05 PMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     HUM is currently down -1.80% on the day, but the most relevant news is actually bullish: UnitedHealth beat Q3 expectations and raised guidance, with headlines explicitly noting Humana advancing 2% on the UNH coat-tails (sector read-through on medical cost trends). The current -1.80% move in HUM appears inconsistent with the positive sector catalyst — UNH is up ~4% and HUM should benefit from the same cost-trend narrative. This suggests the early HUM weakness may be fading or that the headline capturing HUM +2% reflects a mid-session reversal already underway from a deeper intraday low. The setup here is a likely REVERSAL (up) rather than continuation of the down move. With 160 minutes remaining, there is ample time for HUM to recover toward the UNH-driven sector bid. The macro backdrop (yield curve steepening, T10Y3M elevated) is modestly negative for recession-sensitive managed care but is not the dominant force today versus the direct earnings catalyst. Probability reflects moderate confidence in upside continuation given the strong sector tailwind, time remaining, and apparent disconnect between HUM's current print and the positive UNH read-through.

153. ?Oct 13, 11:35 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is down -3.48% on the session, but the most recent headlines from mid-session show a meaningful reversal catalyst: UNH beat Q3 and raised guidance with positive cost commentary (AI-driven efficiency), and at least one headline explicitly notes 'Humana Advances 2%' following that UNH print. Additionally, HUM announced a joint venture with BlackRock for 150 senior care clinics — a strategic positive. The gap down at open was likely driven by pre-headline anxiety or sector rotation, but the sector backdrop has since improved materially. With 250 minutes remaining (well over 4 hours — this is mid-morning, not late session), there is ample time for the positive UNH read-through and HUM's own JV news to attract buyers. The macro context (elevated T10Y3M) is modestly headwind for recession-sensitive names, but managed care is more influenced by medical cost trends than yield curve shape. The setup favors a reversal/fade of the morning gap down rather than continuation lower. Probability assigned to upward continuation (fade of the down move) at 0.55 — positive newsflow supports recovery but the initial gap magnitude and macro uncertainty prevent a higher conviction call.

154. !Oct 13, 11:35 AMsignalseverity -0.03

     Agent 7 — Day Trader — day_trade_skipped

     HUM is down -3.48% on the session, but the most recent headlines from mid-session show a meaningful reversal catalyst: UNH beat Q3 and raised guidance with positive cost commentary (AI-driven efficiency), and at least one headline explicitly notes 'Humana Advances 2%' following that UNH print. Additionally, HUM announced a joint venture with BlackRock for 150 senior care clinics — a strategic positive. The gap down at open was likely driven by pre-headline anxiety or sector rotation, but the sector backdrop has since improved materially. With 250 minutes remaining (well over 4 hours — this is mid-morning, not late session), there is ample time for the positive UNH read-through and HUM's own JV news to attract buyers. The macro context (elevated T10Y3M) is modestly headwind for recession-sensitive names, but managed care is more influenced by medical cost trends than yield curve shape. The setup favors a reversal/fade of the morning gap down rather than continuation lower. Probability assigned to upward continuation (fade of the down move) at 0.55 — positive newsflow supports recovery but the initial gap magnitude and macro uncertainty prevent a higher conviction call.

155. ?Oct 13, 10:05 AMdecisionconsidered

     Agent 7 — Day Trader — analyze: fail

     Claude analysis failed: Unexpected non-whitespace character after JSON at position 63 (line 6 column 1)

156. ?Oct 8, 11:10 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is down 4.08% today, a meaningful move indicating real selling pressure and institutional conviction. The gap-down nature (flagged in the S&P500 gap screen headline) suggests the move opened with force rather than drifted lower, which typically reflects overnight/pre-market catalyst-driven flow. No clear reversal pattern is evident from the data provided. The macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend — this is a headwind for rate-sensitive sectors, and managed care names like HUM carry interest-rate sensitivity through investment portfolio dynamics and discount rate assumptions on future cash flows. With 275 minutes remaining (roughly 4.5 hours), there is ample time for the move to extend further into the close. The absence of a specific fundamental catalyst is not a disqualifier — the gap screen suggests broad-based selling context. However, a 4% move already absorbed reduces the expected incremental downside, and without a confirmed news driver, some mean-reversion risk exists. On balance, moderate continuation probability is warranted — the momentum is real, time is sufficient, and macro backdrop is modestly supportive of continued pressure on this name.

157. ?Oct 1, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     The most significant concern is the upcoming earnings on 2026-11-06 (36 days away) with a consensus EPS of -$0.93, indicating analysts expect a loss — a meaningful fundamental warning signal for a managed care company. While earnings are not within the 14-day hard veto window, they fall in the 15-30 day zone, applying a meaningful headwind (-1). The drop is only 10.2%, below the 15% mean-reversion threshold, and the options flow (P/C ratio 0.84) shows modestly more calls than puts but no unusual call volume spike. The sector (Health Care) has mild relative weakness but is not in freefall. There are no insider buys, no cluster buying signal, and the 10Y yield at 5.26% is a structural headwind for a Medicare-exposed insurer with rate sensitivity. Net signal score: earnings headwind (-1), high 10Y yield (-1), no cluster buy (0), no unusual call volume (0), no fundamental deterioration confirmed but negative EPS consensus is concerning — netting roughly -1 to -2, below the buy threshold.

158. ?Oct 1, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     The 10.2% dip is moderate, but the most alarming signal is the upcoming earnings on 2026-11-06 (36 days away) with a consensus EPS of -$0.93 — a loss — which points to confirmed fundamental deterioration rather than a temporary overreaction. The 8-K filed September 1st with no disclosed metrics is opaque and adds uncertainty. Options flow is modestly bullish (P/C 0.84, calls > puts) but lacks z-score confirmation of unusual activity, and there are no insider buys to support a contrarian thesis. News is neutral-to-mildly-positive around 2027 Medicare Advantage plan offerings, but this is routine and not a strong recovery catalyst.

159. ✓Sep 25, 6:21 PMdecisionacted

     Agent 20 — SIR Price/Volume — buy

     [cluster_break_up] From 2026-09-15 through 2026-09-24, HUM carved out a tight low-price cluster ranging roughly $372–$386 on subdued volume (758K–1.0M, well within the 919K ADV), forming a clear base in 2-D PV space. Today's bar on 2026-09-25 breaks decisively above that entire cluster — closing at $397.93 (+4.63%) on 1.9M shares, a volume z-score of +4.69 versus the trailing 20-day mean — indicating a surge of fresh demand absorbing the float accumulated during the consolidation. The prior up-leg (2026-09-01 through 2026-09-11, peaking at $409.80) on similarly modest volume gives context: this break is re-attacking the prior range highs with materially expanded participation, consistent with the SIR cluster_break_up pattern where expanding volume on a decisive price move above a congestion zone signals institutional-grade sponsorship. Risks: A failure to follow through above the $400–$409 resistance band (the prior September 1–11 cluster) on subsequent sessions — particularly any reversal back into the $380s on rising volume — would invalidate the breakout and suggest today's bar was a single-session spike without durable demand. Additionally, the elevated 5-year inflation breakeven (T5YIFR at 2.33, +1.6σ above trend) poses a macro headwind for rate-sensitive Health Care names; a further breakeven spike or hawkish repricing could pressure the sector and undercut the setup before multi-session confirmation accumulates.

160. ?Sep 25, 10:15 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     HUM is up 2.47% intraday with no attributable headline, suggesting quiet but real institutional flow rather than a news-driven spike that might reverse on profit-taking. The move is meaningful in magnitude and represents genuine conviction from someone with size. With 330 minutes remaining (essentially the full afternoon session), there is ample time for continuation. The macro context shows the 5-year forward inflation rate at 1.6σ above trend — elevated inflation expectations can modestly pressure managed care names via cost assumptions, but HUM's move is already upward, so this macro headwind does not appear to be dominating today's tape. The absence of news is not a disqualifier per the framework. No reversal signals or fade pattern is visible. However, confidence is tempered by: (1) no clear catalyst to anchor the thesis, (2) the inflation backdrop is at least a mild sector headwind, and (3) HUM is a volatile name where 2-3% intraday moves can retrace without a fundamental anchor. Net assessment: modest continuation bias; ordinary momentum read with no strong reason to fade.

161. ?Sep 24, 1:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     HUM is down 10.1% from its 30-day high with no visible fundamental deterioration in recent filings and no headlines explaining the drop, but several soft negatives weigh on the thesis. The upcoming earnings on 2026-11-06 (46 days away) is not an immediate veto but is a meaningful headwind (-1); consensus EPS of -$0.93 is deeply negative, signaling potential fundamental pressure in the managed care segment. Health Care sector is outperforming the market (rank 2 of 11, +3.29pts vs SPY over 30 days), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.94% is above the 4.5% threshold, a structural headwind (-1). On the positive side, call/put ratio is a modest 0.59 (not unusually bullish), no insider activity is present, and the drop is only 10.1% (below the 15% mean-reversion threshold). Net signal score: approximately -2 to -3, which does not support a buy. The base rate of ~55-60% is pulled down materially by idiosyncratic risk, a consensus loss EPS, and high rates.

162. ?Sep 24, 1:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.8% from its 30-day high with no clear negative fundamental catalyst visible — no news headlines, no insider selling, and the 8-K filed September 1 provides no reported adverse metrics. The options flow shows a moderately bullish P/C ratio of 0.72 with call volume exceeding put volume, a mild positive signal. However, the upcoming earnings on November 6 (43 days away) carry a consensus EPS estimate of -$0.93, a loss expectation that is a meaningful headwind, and the elevated 10Y yield at 4.96% is a structural headwind for rate-sensitive managed care companies. The Health Care sector is showing mixed relative strength (slightly positive 30d but negative 5d vs SPY), and the sector-wide flow proxy is deeply negative today, suggesting the dip may be partly sector-driven rather than idiosyncratic.

163. ?Sep 24, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.8% from its 30-day high with no clear negative fundamental catalyst visible — no news headlines, no insider selling, and the 8-K filed September 1 provides no reported adverse metrics. The options flow shows a moderately bullish P/C ratio of 0.72 with call volume exceeding put volume, a mild positive signal. However, the upcoming earnings on November 6 (43 days away) carry a consensus EPS estimate of -$0.93, a loss expectation that is a meaningful headwind, and the elevated 10Y yield at 4.96% is a structural headwind for rate-sensitive managed care companies. The Health Care sector is showing mixed relative strength (slightly positive 30d but negative 5d vs SPY), and the sector-wide flow proxy is deeply negative today, suggesting the dip may be partly sector-driven rather than idiosyncratic.

164. ?Sep 24, 10:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     HUM is down 10.1% from its 30-day high with no visible fundamental deterioration in recent filings and no headlines explaining the drop, but several soft negatives weigh on the thesis. The upcoming earnings on 2026-11-06 (46 days away) is not an immediate veto but is a meaningful headwind (-1); consensus EPS of -$0.93 is deeply negative, signaling potential fundamental pressure in the managed care segment. Health Care sector is outperforming the market (rank 2 of 11, +3.29pts vs SPY over 30 days), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.94% is above the 4.5% threshold, a structural headwind (-1). On the positive side, call/put ratio is a modest 0.59 (not unusually bullish), no insider activity is present, and the drop is only 10.1% (below the 15% mean-reversion threshold). Net signal score: approximately -2 to -3, which does not support a buy. The base rate of ~55-60% is pulled down materially by idiosyncratic risk, a consensus loss EPS, and high rates.

165. ?Sep 24, 7:04 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.8% from its 30-day high with no clear negative fundamental catalyst visible — no news headlines, no insider selling, and the 8-K filed September 1 provides no reported adverse metrics. The options flow shows a moderately bullish P/C ratio of 0.72 with call volume exceeding put volume, a mild positive signal. However, the upcoming earnings on November 6 (43 days away) carry a consensus EPS estimate of -$0.93, a loss expectation that is a meaningful headwind, and the elevated 10Y yield at 4.96% is a structural headwind for rate-sensitive managed care companies. The Health Care sector is showing mixed relative strength (slightly positive 30d but negative 5d vs SPY), and the sector-wide flow proxy is deeply negative today, suggesting the dip may be partly sector-driven rather than idiosyncratic.

166. ?Sep 24, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     HUM is down 10.1% from its 30-day high with no visible fundamental deterioration in recent filings and no headlines explaining the drop, but several soft negatives weigh on the thesis. The upcoming earnings on 2026-11-06 (46 days away) is not an immediate veto but is a meaningful headwind (-1); consensus EPS of -$0.93 is deeply negative, signaling potential fundamental pressure in the managed care segment. Health Care sector is outperforming the market (rank 2 of 11, +3.29pts vs SPY over 30 days), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.94% is above the 4.5% threshold, a structural headwind (-1). On the positive side, call/put ratio is a modest 0.59 (not unusually bullish), no insider activity is present, and the drop is only 10.1% (below the 15% mean-reversion threshold). Net signal score: approximately -2 to -3, which does not support a buy. The base rate of ~55-60% is pulled down materially by idiosyncratic risk, a consensus loss EPS, and high rates.

167. ?Sep 23, 6:02 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     HUM is down 11.4% from its 30-day high with no company-specific negative news headlines or meaningful SEC filing metrics to explain the drop, suggesting the decline is more macro/sector-driven than fundamental deterioration. However, the macro context is a headwind: the 5-year forward inflation rate (T5YIFR) is printing 1.9σ above its 24-month trend, which pressures rate-sensitive and cost-sensitive sectors like managed care, where medical cost trends and investment income are both affected by the rate environment. Humana remains a large, established managed care organization with no visible signs of guidance cuts or accounting issues, but the broader managed care sector has faced persistent Medical Loss Ratio (MLR) pressure in recent periods, which warrants caution.

168. ?Sep 23, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     HUM is down 10.1% from its 30-day high with no visible fundamental deterioration in recent filings and no headlines explaining the drop, but several soft negatives weigh on the thesis. The upcoming earnings on 2026-11-06 (46 days away) is not an immediate veto but is a meaningful headwind (-1); consensus EPS of -$0.93 is deeply negative, signaling potential fundamental pressure in the managed care segment. Health Care sector is outperforming the market (rank 2 of 11, +3.29pts vs SPY over 30 days), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.94% is above the 4.5% threshold, a structural headwind (-1). On the positive side, call/put ratio is a modest 0.59 (not unusually bullish), no insider activity is present, and the drop is only 10.1% (below the 15% mean-reversion threshold). Net signal score: approximately -2 to -3, which does not support a buy. The base rate of ~55-60% is pulled down materially by idiosyncratic risk, a consensus loss EPS, and high rates.

169. ?Sep 23, 4:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     HUM is down 10.1% from its 30-day high with no identifiable catalyst — no headlines, no meaningful SEC filing metrics, and no insider buying activity to signal insider confidence. The options flow is modestly bullish (P/C ratio 0.59) and the Health Care sector is showing relative strength (rank 2/11, outperforming SPY), which means HUM's dip appears idiosyncratic rather than sector-driven, warranting investigation into the cause. However, the most significant headwind is the upcoming earnings on 2026-11-06 (46 days away) with a consensus EPS of -$0.93, suggesting analysts expect a loss — this is a material negative signal that raises the probability of further downside pressure and limits rebound potential ahead of a potentially disappointing print.

170. ?Sep 23, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     HUM is down 10.1% from its 30-day high with no visible fundamental deterioration in recent filings and no headlines explaining the drop, but several soft negatives weigh on the thesis. The upcoming earnings on 2026-11-06 (46 days away) is not an immediate veto but is a meaningful headwind (-1); consensus EPS of -$0.93 is deeply negative, signaling potential fundamental pressure in the managed care segment. Health Care sector is outperforming the market (rank 2 of 11, +3.29pts vs SPY over 30 days), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.94% is above the 4.5% threshold, a structural headwind (-1). On the positive side, call/put ratio is a modest 0.59 (not unusually bullish), no insider activity is present, and the drop is only 10.1% (below the 15% mean-reversion threshold). Net signal score: approximately -2 to -3, which does not support a buy. The base rate of ~55-60% is pulled down materially by idiosyncratic risk, a consensus loss EPS, and high rates.

171. ▢Jun 3, 8:00 PMjournal

     Agent 7 — Day Trader opened long 4 @ $348.01

172. ▣Jun 3, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 4 @ $349.11 (+$4.40)

     EOD forced close — day trader never carries overnight